Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

HDV is intended to address the difficulty of insulin, GLP-1, or other molecules traveling to the liver when injected subcutaneously, due to the large number of receptors in peripheral tissue such as fat cells and muscle cells. The post Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data appeared first on GEN - Genetic Engineering and Biotechnology News.
This is a short summary. The full story is published by Gen.
Read full story at Gen